Price breadth, unusual activity and signed capital flow are separate observations
Price sequence unavailableA timestamped price sequence is unavailable.
RELATIVE CO-MOVEMENT
How the members are behaving together
Session-normalized
Observed intraday paths are not available for this group yet.
02 · WHY IT MATTERS
Why now and where the move could travel
Context and lead/lag links are evidence, not proof of causation or a forecast
WHY NOW
Verified recent context
0 items
No verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.
WHY THIS GROUP EXISTS
Shared filing context
8/12 members covered
Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across AMRX, ESTA, EW, INCY, KYMR, LGND, NUVB, VRTX.
product pipeline / R&D affecting expense
“The increase of $13.7 million was primarily due to a $8.3 million increase in costs related to our STAT6 program, a $6.1 million increase in personnel, stock-based compensation, occupancy, and other internal costs due to increase investment in employee talent and facilities in the research and development functions partially offset by a $0.7 million decrease in costs related to our other clinical and preclinical programs.”
“All of our European Union trademarks in existence as of December 31, 2020 were automatically cloned onto the United Kingdom register due to “Brexit.” As of December 31, 2025, our trademark portfolio includes registrations, pending and allowed applications of the KYMERA mark and the KYMERA THERAPEUTICS mark, and the KT mark in the United States, Europe, and Canada, all covering Class 5 pharmaceutical and medical preparations and therapeutics and Class 42 pharmaceutical research and development and drug development and discovery services.”
“We are also eligible to receive tiered royalties on net sales by Gilead ranging from high single-digit to mid-teen percentages, subject to customary reductions in certain circumstances Operating expenses Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative expenses.”
Not participating yet; a breadth test or a genuine divergence.
04 · HAS THIS HAPPENED BEFORE
Identity history versus measured outcomes
Structural recurrence is not the same as a validated trading outcome
POINT-IN-TIME LIVE OUTCOMES
Live outcome ledger collecting
0/0 events completed
No completed point-in-time outcome is available yet. New live confirmations are now retained with their exact observation timestamp; statistics appear only after the corresponding candles complete.
Low structural sample
Only 0 completed episodes across 0 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.
Structural support11 daysHow often the cohort identity was observed
Completed episodes0Separate periods of broad group activity
Active sessions0Completed session observations, not trades